Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Thymosin Alpha-1 Dosing: 1.5mg 5on/2off Protocol (2026)

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you. Where These Numbers Come From Thymosin alpha-1 has one of the strongest clinical evidence

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Thymosin alpha-1 has one of the strongest clinical evidence bases of any peptide in the research community.

Immune Modulation: A comprehensive review confirmed thymosin alpha-1's pleiotropic effects on T-cells, NK cells, dendritic cells, and macrophages — restoring immune function across diverse clinical settings (Tuthill et al., 2016).

Hepatitis B Trials: Thymalfasin was extensively studied at 1.6 mg twice weekly for 6-12 months, showing improved virological response and enhanced vaccine responsiveness in immunocompromised patients.

Sepsis Data: A large Phase III trial (TESTS) evaluated thymosin alpha-1 at 1.6 mg in sepsis patients, providing significant data on immune modulation in critical illness (Li et al., 2025). An earlier meta-analysis showed trends toward reduced mortality from multiple organ failure (Li et al., 2015).

Safety Review: A narrative review covering 11,000+ subjects across 30+ trials confirmed an excellent safety profile with no dose-limiting toxicities (Dinetz et al., 2024).

Stacking Protocols

Thymosin Alpha-1 + LL-37 (Immune Defense Stack)

Thymosin alpha-1

1.5 mg

SC

5on/2off, AM

Adaptive immune modulation (T-cells, NK cells)

LL-37

50-100 mcg

Daily or 3x/week

Innate immune defense (antimicrobial)

Thymosin Alpha-1 + Thymulin

Broad immune modulation

Thymulin

2 mg

PM

T-cell maturation (zinc-dependent)

Complementary thymic peptides — TA-1 acts downstream on function, thymulin acts upstream on development.

Thymosin Alpha-1 + BPC-157

Immune support

BPC-157

250-500 mcg

Daily

Tissue repair, gut healing

Side Effects & Safety

Injection site reactions — mild erythema, minor discomfort (most common, transient)

No dose-limiting toxicities identified across 30+ clinical trials

No significant organ toxicity reported in 11,000+ subjects

No immune overstimulation — modulates rather than simply stimulates immunity

Safe in immunocompromised — extensively used in HIV, hepatitis, and cancer patients

Autoimmune conditions: Clinical context — trials have not specifically studied this population; immune modulation effects may warrant clinical monitoring

Organ transplant: Clinical context — immune enhancement could theoretically affect transplant tolerance; not studied in transplant populations

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once thymosin alpha-1 is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

1 mg

0.2 mL

20 units

0.3 mL

30 units

0.4 mL

40 units

3 mg

0.6 mL

60 units

Reconstitution B: 10 mg vial + 1 mL BAC water (10 mg/mL) — less BAC water for a lower total volume, so smaller draws and less fridge space.

0.1 mL

10 units

0.15 mL

15 units

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.

Core Supplies for This Protocol

The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking.

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Future research

Peptides have huge therapeutic value. Significant research has taken place over the years. It has successfully treated a wide range of diseases. It’s also used in aesthetic treatments. Many people feel comfortable in using this safe and natural approach to their health. There’s great potential for this market to increase. Investments into this area of research seem positive. Continuous support from the government and investors can increase COVID research. With the success of this treatment, there’s a need to make more of them available. Phase 3 trial in hepatitis C is still in progress. The same applies to phase 2 in hepatitis B. There are also efforts underway to improve oral availability. To make it more permeable for the GI tract.